Controlling Esophageal Disease in Children...Beyond the Acid
Release Date:
December 2007
Expiration Date: December 31, 2009
Introduction:
The role of acid in various pediatric esophageal disorders has been studied extensively. However, there is a need to understand how factors other than acid may influence esophageal dysfunction. Researchers exploring these factors face several questions: What is the role of nonacid reflux in exacerbating GERD symptoms? If patients don't respond to acid-suppressive therapies, what diagnostic and treatment tools do clinicians have at their disposal? Are pediatric esophageal disorders related to gastrointestinal motility or acid? Are eosinophils in the esophagus a result of acid, allergens, or something else?
Providing insight and answers to these questions are 4 distinguished GERD thought leaders, who will discuss issues in pediatric GERD that go beyond acid reflux. This program will address cutting-edge information and how it fits into clinical practice. By featuring brief lectures and interactive Q&A sessions, this online activity is aimed at enhancing audience involvement as well as providing answers to burning questions on esophageal dysfunction in the pediatric population.
Learning
Objectives:
- Differentiate between motility-related, inflammatory, and acid reflux disorders that contribute to esophageal disease in children
- Discuss the mechanisms of acid and nonacid reflux in GERD
- Review recently published literature on the available therapeutic options for both adults and children with GERD
- Provide an overview of eosinophilic esophagitis in children and its relation to acid reflux-associated and "allergic" inflammation
Target Audience:
This activity is designed for physicians, pharmacists, nurse practitioners, and nurses with a special interest in gastroenterology. This online activity will consist of a slide lecture with audio from a live symposium.
Accreditation:
Physicians:
This activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for Continuing
Medical Education through the joint sponsorship of the Dannemiller Memorial
Educational Foundation and The Customer Link, Inc. The Dannemiller Memorial
Educational Foundation is accredited by the ACCME to provide continuing
medical education for physicians.
The Dannemiller Memorial Educational
Foundation designates this educational activity for a maximum of 1.5 AMA
PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Pharmacists:
 Purdue
University is accredited by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education. This program is a continuing education
activity of Purdue University, an equal access/equal opportunity institution. Universal Program Number (UPN) #018-999-07-202-H01-P, 1.5 contact hours (0.15 CEU). Release Date: December 26, 2007. Expiration Date: December 26, 2009.
Nurse Practitioners:
This program has been approved for 1.5 contact hours of continuing education (which includes .40 hours of pharmacology) by the American Academy of
Nurse Practitioners. Program ID 0711513.
Nurses:
The Dannemiller Memorial Educational Foundation is an approved provider
of the California Board of Registered Nursing. Provider approved by the
California Board of Registered Nursing, Provider Number 4229 for 1.8 contact
hours.
RNs outside California must verify with their licensing agency
for approval of this course.
Physician Assistants:
AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by ACCME.
Chair:
Benjamin D. Gold, MD
Professor of Pediatrics and Microbiology
Marcus Professor and Director
Pediatric Gastroenterology, Hepatology and Nutrition
Department of Pediatrics
Emory University School of Medicine and Health Sciences
Atlanta, GA
Faculty:
Samuel Nurko, MD, MPH
Associate Professor of Pediatrics
Harvard Medical School
Director,
Center for Motility and Functional Gastrointestinal Disorders
Children's Hospital Boston
Boston, MA
Donald Castell, MD
Professor of Medicine
Director of Esophageal Disorders Program
Digestive Disease Center
Medical University of South Carolina
Charleston, SC
Glenn T. Furuta, MD
Associate Professor
University of Colorado at Denver and Health Sciences Center
Denver, CO
Disclosures:
In
accordance with the Accreditation Council for Continuing Medical Education (ACCME),
the Dannemiller Memorial Educational Foundation requires that any person who is
in a position to control the content of a CME activity must disclose all relevant
financial relationships they have with a commercial interest. Accordingly:
Dr. Castell reported that he is a speaker and consultant for Santarus, Inc. and Sandhill Scientific. He is also a consultant and investigator for Pfizer Inc. and XenoPort.
Dr. Furuta reported that he is a consultant for Ception Therapeutics and a speaker for TAP Pharmaceuticals Products Inc.
Dr. Gold reported that he is a speaker for TAP Pharmaceutical Products Inc. and Nestlé USA. He is a consultant for TAP Pharmaceutical Products Inc.; AstraZeneca; Santarus, Inc.; and Nestlé USA. He also reported that he is an investigator for TAP Pharmaceutical Products Inc.
Dr. Nurko reported that he is an investigator for TAP Pharmaceutical Products Inc.
The Dannemiller staff and Customer Link staff that were involved in the development of this activity have no financial relationships with any commercial interests that are relevant to this activity.
To resolve identified conflicts of interest, the educational content was fully peer-reviewed by a physician member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.
Disclosure
of Unlabeled or Investigational Drugs:
This educational activity may contain discussion
of published and/or investigational uses of agents that are not indicated by the
FDA. The opinions expressed in the educational activity are those of the faculty.
Please refer to the official prescribing information for each product for discussion
of approved indications, contraindications, and warnings. Further, attendees/participants
should appraise the information presented critically and are encouraged to consult
appropriate resources for any product or device mentioned in this program.
Disclaimer:
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of The Dannemiller
Memorial Educational Foundation, TAP Pharmaceutical Products Inc., or
The Customer Link, Inc. This material is prepared based upon a review
of multiple sources of information, but it is not exhaustive of the subject
matter.
Therefore, healthcare professionals
and other individuals should review and consider other publications and materials
on the subject matter before relying solely upon the information contained within
this educational activity.
Method of Participation:
This activity should take approximately 1.5 hours
to complete. The participant should:
- Read
the objectives and other CME/CPE/CE information.
- Listen to the audio while viewing the slides: Please note that this program was recorded, and as a result, participants will not have the opportunity to ask questions of the presenter.
- Take the
post-test.
- Complete
the evaluation and registration information. The evaluation on the post-test site provides you with the opportunity to comment on the extent to which the educational needs were met, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and your view on future educational needs.
- Participants
who complete the post-test and evaluation will be issued a CME/CPE/CE certificate,
which may be printed at their location. A database of certificates awarded
online is maintained at the Dannemiller Foundation. No additional certificate
will be mailed. If you have any questions, you may contact the Dannemiller
Foundation at editor@dannemiller.com. Expiration date for credit is December 31, 2009.
Software
Requirements:
| 
